Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Publikation

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Wissenschaftlicher Artikel/Review - 20.06.2018

Beumer Jan H, Boku Narikazu, Muneoka Katsuki, Arnold Dirk, Zhang Li, Mathijssen Ron H, Kim Tae Won, Diasio Robert, Milano Gerard, Tanigawara Yusuke, Allegra Carmen, Chu Edward, Jörger Markus

Zitation

Beumer J, Boku N, Muneoka K, Arnold D, Zhang L, Mathijssen R, Kim T, Diasio R, Milano G, Tanigawara Y, Allegra C, Chu E, Jörger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 2018

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Clin Pharmacol Ther 2018

Veröffentlichungsdatum

20.06.2018

eISSN (Online)

1532-6535

Kurzbeschreibung/Zielsetzung

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.